Fig. 4

Median progression-free survival (PFS) in months as reported in trials of Gliadel wafers combined with standard radiotherapy (RT) and concurrent followed by adjuvant temozolomide (TMZ) for the treatment of high-grade glioma. The median PFS values of these trials are compared with the values for the active treatment arm of the 240-patient phase III clinical trial of Gliadel wafers plus RT [8, 10] (column 1) and the active treatment arm of the phase III clinical trial of RT/TMZ (column 2) [11, 12]